http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 21 Jul 2026 06:03:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Jul+21/26791563.html si-local-file:///var/storage/secattach/20260721/26791563.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Jul+21/26791563.html Tue, 21 Jul 2026 06:03:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Jul+21/26791563.html si-local-file:///var/storage/secattach/20260721/26791563.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Jul+21/26791563.html Tue, 21 Jul 2026 06:03:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Jul+21/26791563.html si-local-file:///var/storage/secattach/20260721/26791563.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Jul+21/26791563.html Tue, 21 Jul 2026 06:03:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Jul+14/26770247.html si-local-file:///var/storage/secattach/20260715/26770247.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Jul+14/26770247.html Wed, 15 Jul 2026 06:06:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Jul+14/26770247.html si-local-file:///var/storage/secattach/20260715/26770247.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Jul+14/26770247.html Wed, 15 Jul 2026 06:06:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Jul+14/26770247.html si-local-file:///var/storage/secattach/20260715/26770247.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Jul+14/26770247.html Wed, 15 Jul 2026 06:06:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Jul+14/26764929.html si-local-file:///var/storage/secattach/20260714/26764929.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Jul+14/26764929.html Tue, 14 Jul 2026 07:55:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Jul+14/26764929.html si-local-file:///var/storage/secattach/20260714/26764929.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Jul+14/26764929.html Tue, 14 Jul 2026 07:55:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Jul+14/26764929.html si-local-file:///var/storage/secattach/20260714/26764929.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Jul+14/26764929.html Tue, 14 Jul 2026 07:55:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/FDA/Mesoblast+reaches+300-patient+enrollment+in+back+pain+Phase+3+trial/26763495.html <p>Mesoblast Limited (Nasdaq: MESO; ASX: MSB) said it has enrolled and treated at least 300 patients in its MSB-DR004 pivotal Phase 3 randomized controlled trial of rexlemestrocel-L for chronic low back pain associated with degenerative disc disease.</p> <p>The trial's primary endpoint is designed to show a statistically significant difference in pain reduction at 12 months between rexlemestrocel-L and a sham control group. Secondary endpoints include improvements in function, quality of life, and cessation of pain medication, including opioids. Top-line results are expected in mid-2027, after the last treated patient completes 12 months of follow-up.</p> <p>Rexlemestrocel-L holds Regenerative Medicine Advanced Therapy designation from http://www.streetinsider.com/FDA/Mesoblast+reaches+300-patient+enrollment+in+back+pain+Phase+3+trial/26763495.html Mon, 13 Jul 2026 20:35:57 -0400 MESO MSB O.01273089 http://www.streetinsider.com/FDA/Mesoblast+reaches+300-patient+enrollment+in+back+pain+Phase+3+trial/26763495.html <p>Mesoblast Limited (Nasdaq: MESO; ASX: MSB) said it has enrolled and treated at least 300 patients in its MSB-DR004 pivotal Phase 3 randomized controlled trial of rexlemestrocel-L for chronic low back pain associated with degenerative disc disease.</p> <p>The trial's primary endpoint is designed to show a statistically significant difference in pain reduction at 12 months between rexlemestrocel-L and a sham control group. Secondary endpoints include improvements in function, quality of life, and cessation of pain medication, including opioids. Top-line results are expected in mid-2027, after the last treated patient completes 12 months of follow-up.</p> <p>Rexlemestrocel-L holds Regenerative Medicine Advanced Therapy designation from http://www.streetinsider.com/FDA/Mesoblast+reaches+300-patient+enrollment+in+back+pain+Phase+3+trial/26763495.html Mon, 13 Jul 2026 20:35:57 -0400 MESO MSB O.01273089 http://www.streetinsider.com/FDA/Mesoblast+reaches+300-patient+enrollment+in+back+pain+Phase+3+trial/26763495.html <p>Mesoblast Limited (Nasdaq: MESO; ASX: MSB) said it has enrolled and treated at least 300 patients in its MSB-DR004 pivotal Phase 3 randomized controlled trial of rexlemestrocel-L for chronic low back pain associated with degenerative disc disease.</p> <p>The trial's primary endpoint is designed to show a statistically significant difference in pain reduction at 12 months between rexlemestrocel-L and a sham control group. Secondary endpoints include improvements in function, quality of life, and cessation of pain medication, including opioids. Top-line results are expected in mid-2027, after the last treated patient completes 12 months of follow-up.</p> <p>Rexlemestrocel-L holds Regenerative Medicine Advanced Therapy designation from http://www.streetinsider.com/FDA/Mesoblast+reaches+300-patient+enrollment+in+back+pain+Phase+3+trial/26763495.html Mon, 13 Jul 2026 20:35:57 -0400 MESO MSB O.01273089 http://www.streetinsider.com/Press+Releases/Mesoblast+Achieves+Target+of+300+Treated+Patients+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26763494.html <p align="justify">NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its target of at least 300 patients treated in the MSB-DR004 pivotal Phase 3 randomized controlled trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with degenerative disc disease. The trial aims to confirm the durable pain reduction from a single intra-discal injection of rexlemestrocel-L seen in the earlier MSB-DR003 trial.</p> <p align="justify">Silviu Itescu, Chief Executive of Mesoblast, said: “Completing our target of treating at least 300 patients http://www.streetinsider.com/Press+Releases/Mesoblast+Achieves+Target+of+300+Treated+Patients+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26763494.html Mon, 13 Jul 2026 20:35:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/Press+Releases/Mesoblast+Achieves+Target+of+300+Treated+Patients+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26763494.html <p align="justify">NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its target of at least 300 patients treated in the MSB-DR004 pivotal Phase 3 randomized controlled trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with degenerative disc disease. The trial aims to confirm the durable pain reduction from a single intra-discal injection of rexlemestrocel-L seen in the earlier MSB-DR003 trial.</p> <p align="justify">Silviu Itescu, Chief Executive of Mesoblast, said: “Completing our target of treating at least 300 patients http://www.streetinsider.com/Press+Releases/Mesoblast+Achieves+Target+of+300+Treated+Patients+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26763494.html Mon, 13 Jul 2026 20:35:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/Press+Releases/Mesoblast+Achieves+Target+of+300+Treated+Patients+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26763494.html <p align="justify">NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its target of at least 300 patients treated in the MSB-DR004 pivotal Phase 3 randomized controlled trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with degenerative disc disease. The trial aims to confirm the durable pain reduction from a single intra-discal injection of rexlemestrocel-L seen in the earlier MSB-DR003 trial.</p> <p align="justify">Silviu Itescu, Chief Executive of Mesoblast, said: “Completing our target of treating at least 300 patients http://www.streetinsider.com/Press+Releases/Mesoblast+Achieves+Target+of+300+Treated+Patients+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26763494.html Mon, 13 Jul 2026 20:35:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/Globe+Newswire/Mesoblast+Achieves+Target+of+300+Treated+Patients+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26763494.html <p align="justify">NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its target of at least 300 patients treated in the MSB-DR004 pivotal Phase 3 randomized controlled trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with degenerative disc disease. The trial aims to confirm the durable pain reduction from a single intra-discal injection of rexlemestrocel-L seen in the earlier MSB-DR003 trial.</p> <p align="justify">Silviu Itescu, Chief Executive of Mesoblast, said: “Completing our target of treating at least 300 patients http://www.streetinsider.com/Globe+Newswire/Mesoblast+Achieves+Target+of+300+Treated+Patients+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26763494.html Mon, 13 Jul 2026 20:35:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/Globe+Newswire/Mesoblast+Achieves+Target+of+300+Treated+Patients+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26763494.html <p align="justify">NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its target of at least 300 patients treated in the MSB-DR004 pivotal Phase 3 randomized controlled trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with degenerative disc disease. The trial aims to confirm the durable pain reduction from a single intra-discal injection of rexlemestrocel-L seen in the earlier MSB-DR003 trial.</p> <p align="justify">Silviu Itescu, Chief Executive of Mesoblast, said: “Completing our target of treating at least 300 patients http://www.streetinsider.com/Globe+Newswire/Mesoblast+Achieves+Target+of+300+Treated+Patients+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26763494.html Mon, 13 Jul 2026 20:35:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/Globe+Newswire/Mesoblast+Achieves+Target+of+300+Treated+Patients+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26763494.html <p align="justify">NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its target of at least 300 patients treated in the MSB-DR004 pivotal Phase 3 randomized controlled trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with degenerative disc disease. The trial aims to confirm the durable pain reduction from a single intra-discal injection of rexlemestrocel-L seen in the earlier MSB-DR003 trial.</p> <p align="justify">Silviu Itescu, Chief Executive of Mesoblast, said: “Completing our target of treating at least 300 patients http://www.streetinsider.com/Globe+Newswire/Mesoblast+Achieves+Target+of+300+Treated+Patients+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26763494.html Mon, 13 Jul 2026 20:35:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Jul+10/26754837.html si-local-file:///var/storage/secattach/20260710/26754837.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Jul+10/26754837.html Fri, 10 Jul 2026 06:03:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Jul+10/26754837.html si-local-file:///var/storage/secattach/20260710/26754837.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Jul+10/26754837.html Fri, 10 Jul 2026 06:03:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Jul+10/26754837.html si-local-file:///var/storage/secattach/20260710/26754837.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Jul+10/26754837.html Fri, 10 Jul 2026 06:03:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/Press+Releases/Ryoncil%C2%AE+Delivers+Net+Revenue+of+US%2436M+for+the+Fourth+Quarter+Ended+30+June+2026/26754188.html <p align="justify">NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced Ryoncil® (remestemcel-L-rknd) net revenue of US$36 million for the quarter and US$115 million for the full year ended June 30, 2026. “We are very pleased with the strong uptake of Ryoncil® since launch, and with revenues that have already exceeded our initial projections,” said Mesoblast Chief Executive Dr. Silviu Itescu.</p> <p align="justify">Dr. Itescu added: “We anticipate continued revenue growth in the coming fiscal year in line with momentum we are seeing across major http://www.streetinsider.com/Press+Releases/Ryoncil%C2%AE+Delivers+Net+Revenue+of+US%2436M+for+the+Fourth+Quarter+Ended+30+June+2026/26754188.html Thu, 09 Jul 2026 20:30:00 -0400 A.06822034 MESO MSB O.01273089 O.20026344 http://www.streetinsider.com/Press+Releases/Ryoncil%C2%AE+Delivers+Net+Revenue+of+US%2436M+for+the+Fourth+Quarter+Ended+30+June+2026/26754188.html <p align="justify">NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced Ryoncil® (remestemcel-L-rknd) net revenue of US$36 million for the quarter and US$115 million for the full year ended June 30, 2026. “We are very pleased with the strong uptake of Ryoncil® since launch, and with revenues that have already exceeded our initial projections,” said Mesoblast Chief Executive Dr. Silviu Itescu.</p> <p align="justify">Dr. Itescu added: “We anticipate continued revenue growth in the coming fiscal year in line with momentum we are seeing across major http://www.streetinsider.com/Press+Releases/Ryoncil%C2%AE+Delivers+Net+Revenue+of+US%2436M+for+the+Fourth+Quarter+Ended+30+June+2026/26754188.html Thu, 09 Jul 2026 20:30:00 -0400 A.06822034 MESO MSB O.01273089 O.20026344 http://www.streetinsider.com/Press+Releases/Ryoncil%C2%AE+Delivers+Net+Revenue+of+US%2436M+for+the+Fourth+Quarter+Ended+30+June+2026/26754188.html <p align="justify">NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced Ryoncil® (remestemcel-L-rknd) net revenue of US$36 million for the quarter and US$115 million for the full year ended June 30, 2026. “We are very pleased with the strong uptake of Ryoncil® since launch, and with revenues that have already exceeded our initial projections,” said Mesoblast Chief Executive Dr. Silviu Itescu.</p> <p align="justify">Dr. Itescu added: “We anticipate continued revenue growth in the coming fiscal year in line with momentum we are seeing across major http://www.streetinsider.com/Press+Releases/Ryoncil%C2%AE+Delivers+Net+Revenue+of+US%2436M+for+the+Fourth+Quarter+Ended+30+June+2026/26754188.html Thu, 09 Jul 2026 20:30:00 -0400 A.06822034 MESO MSB O.01273089 O.20026344 http://www.streetinsider.com/Press+Releases/Ryoncil%C2%AE+Delivers+Net+Revenue+of+US%2436M+for+the+Fourth+Quarter+Ended+30+June+2026/26754188.html <p align="justify">NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced Ryoncil® (remestemcel-L-rknd) net revenue of US$36 million for the quarter and US$115 million for the full year ended June 30, 2026. “We are very pleased with the strong uptake of Ryoncil® since launch, and with revenues that have already exceeded our initial projections,” said Mesoblast Chief Executive Dr. Silviu Itescu.</p> <p align="justify">Dr. Itescu added: “We anticipate continued revenue growth in the coming fiscal year in line with momentum we are seeing across major http://www.streetinsider.com/Press+Releases/Ryoncil%C2%AE+Delivers+Net+Revenue+of+US%2436M+for+the+Fourth+Quarter+Ended+30+June+2026/26754188.html Thu, 09 Jul 2026 20:30:00 -0400 A.06822034 MESO MSB O.01273089 O.20026344